New HIV Agent May Have Antileukemic Properties

Researchers from Italy's University of Palermo investigated the antitumor effects of 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a]benzimidazole (TBZ), a new anti-HIV-1 agent, on human promyelocytic HL60 leukemia, in both a parental and a multidrug resistant form (HL60R).

"HL60R overexpresses P-glycoprotein and, like HL60, lacks p53 protein expression. HL60 and HL60R show similar levels of Bcl-2 protein," S. Grimaudo and colleagues wrote ("Selective Induction of Apoptosis in Multidrug Resistant HL60R Cells by the Thiazolobenzoimidazole Derivative 1-(2,6-difluorophenyl)-1H,3H-thiazolo [3,4-a]...

Want to see the full article?

• Purchase this article for only $3.00